



Figure S4

BCMA Cleavable and Non-cleavable ADCs are highly active against established orthotopic xenograft tumors. **A**, BCMA ADC with cleavable linker and DAR4 demonstrated dose-dependent efficacy against an established orthotopic KMS12BM tumor cell model. **B**, BCMA ADC with non-cleavable linker and DAR4 demonstrated dose-dependent efficacy against an established orthotopic KMS12BM tumor cell model. All tumor cell lines were luciferase-labeled and were inoculated intravenously (IV). All animals were administered a single IV dose of BCMA ADC or NTC ADC twenty-three days after tumor inoculation. All studies were performed in immune compromised NSG mice with $n=7-10$ mice per group. NTC was an anti-BHV ADC. All data shown as mean \pm SEM. Tumor growth was monitored by luminescent imaging twice-weekly on an IVIS imager. Statistics represent RMANOVA with Dunnett's post-hoc test, all groups compared to NTC (**** $p<0.0001$, *** $p<0.001$)